Icagen has received a milestone payment from McNeil Consumer and Specialty Pharmaceuticals from the development of a sickle cell disease.

The payment came after Icagen met with the Food and Drug Administration to discuss Phase Two clinical trial results. The trial produced improvement in the hemolytic anemia that is associated with the disease.

The drug, ICA-17043, is being jointly developed by the two companies.

Icagen: www.icagen.com